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MicroRNAs (miRNAs) are small noncoding RNA 
molecules of 19–25 nt that work in the post-
transcriptional regulation of gene expression and 
controls them in many cellular processes such as 
inflammation, cell-cycle regulation, stress response, 
differentiation, apoptosis, and migration (1). Pairing 
with messenger RNAs (mRNAs) of genes that code 
proteins, they lead to repression or degradation of 
mRNA translation (1-3). Thus, miRNAs have been 
implicated in the regulation of signaling in a cell, 
and their deregulation has been shown to play an 
essential role in the development and progression of 
various kind of diseases such as cancer (4). miRNAs 
can be found in blood, milk, urine and other body 
fluids and their levels have often been reported to be 
altered in patients. Circulating miRNAs became one 
of the most promising biomarkers in oncology for 
early diagnosis, prognosis and therapeutic response 
prediction (5). Now, microRNAs are intensely 
studied as candidates for diagnostic and prognostic 
biomarkers for cancers and predictors of drug 
response. 
Breast cancer is the most common cancer among 
females around the world that is the most prevalent 
cause of death among females suffering from cancer. 
Breast cancer contains 25% of the total number of 
MicroRNAs (miRNAs) are a class of small noncoding RNAs that 
control gene expression by targeting mRNAs and leading to either 
translation repression or RNA degradation. Their aberrant expression 
may be involved in human diseases, including cancer. Breast cancer 
is the most common cancer among females around the world that is 
the most prevalent cause of death among females suffering from 
cancer. Many studies have identified a large number of upregulated 
oncogenic miRNAs and down regulated tumor-suppressor miRNAs 
in this type of cancer. In this review, we provide an overview of the 
biogenesis and role of miRNAs in cancer and summarize the most 
recent studies focusing on distinctive expression of miRNAs and 
their potential to be useful as diagnostic and prognostic biomarkers 
in breast cancer. 
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cancers by 1.7 million cancer cases reported in 2012
(6). Various miRNAs have been recognized, in 
which their expression were deregulated in the blood 
or tissue of patients with breast cancer.  
Here we describe the origins and roles of miRNAs, 
and summarize the most recent studies focusing on 
their distinctive expression in breast cancer. 
Biogenesis of miRNAs  
miRNAs are small (~22 nucleotide long) non-coding 
RNAs that are part of a eukaryote system of 
genomic DNA within the nucleus which cary out 
gene regulation at the RNA level. MiRNAs work as 
post-transcriptional regulators of gene expression by 
base pairing with their target mRNAs. MiRNAs are 
first transcribed by RNA Pol II (7) as parts of longer 
RNA molecules (pri-miRNA)(8). pre-miRNA loops 
(~70 nts) are cleaved from the pri-miRNA by 
RNAse III enzyme and Drosha and transported into 
the cytoplasm by RAN-GTP and Exportin 5 (9). pri-
miRNA will be processed further by Dicer in order 
to construct a ~22 nt long duplex(miRNA:miRNA*) 
(10).  
The miRNA:miRNA* duplex is subsequently 
unwound and the mature miRNA is loaded into 
multi-protein RISC (RNA-induced silencing 
complex) (11) and miRNA* usually degrades. The 
miRNA biogenesis is illustrated in Figure 1. 
Depending on the degree of complementarity 
between the miRNA and its target mRNA sequence, 
mature miRNAs can cause translation inhibition or 
mRNA cleavage. Each miRNA may have multiple 
mRNA targets and each gene can be targeted by 
multiple miRNAs. It has been predicted miRNAs 
regulate more than one third of human genes (12). 
miRNA function in cancer 
Cancer development is the result of several 
complicated processes that involves multiple 
alterations in oncogenes and tumor suppressor genes 
over several years. A great deal of researches already 
determined an important role for miRNAs among 
the many regulatory factors involved in the 
pathogenesis of cancer. miRNAs are up or down 
regulated in tumors in comparison with the normal 
tissues, and they can be considered as oncogenes or 
tumor-suppressors, respectively. They contribute to 
cancer by regulating either oncogenes (tumor 
suppressor miRNA) or tumor suppressors 
(oncomiRs). Most of the time it has been seen that 
oncomiRs, such as miR-17-92 cluster (14) or miR-
21(15), are upregulated and tumor suppressor  
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miRNAs, such as let-7 family, are downregulated
(16).  
Dysregulation of the miRNAs expression leads to 
several disorders in critical biological processes such 
as proliferation, differentiation, apoptosis, EMT
(epithelial mesenchymal transition) and migration 
which results in oncogenesis. As a known example 
of a deregulated miRNA, miR-21 is a miRNA which  
www.thecancerpress.com 
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Figure 1: miRNA biogenesis process. A schematic representation of miRNA biogenesis. Each miRNA is transcribed by RNA poly-
merase II (pri-miRNA) from genomic DNA within the nucleus; pri-miRNA is processed by Drosha-DGCR8 and cleaved to pre-
miRNA. Pre-miRNA is exported to the cytoplasm by exportin 5(XPO5), where it is processed and cleaved by DICER complex to a 
double strand miRNA (miRNA*-miRNA). The duplex is splitted, and only the mature miRNA is loaded into the RISC complex. The 
degree of complimentary of the miRNA  to the 3′ UTR target sequence of the mRNA specifies the mRNA translational inhibition or 
degradation(13). 
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is prevalently upregulated in any kinds of cancer 
(17). miR-21 affects all major pathways of 
carcinogenesis (proliferation, apoptosis, 
angiogenesis and invasion), through its multiple 
targets including PTEN (phosphatase and tensin 
homolog)(18), PDCD4 (tumor suppressor gene 
tropomyosin 4) (19)FasL (pro-apoptotic FAS ligand) 
(20), and TIMP3 (metalloproteinase inhibitor 3 
precursor) (21). 
Moreover an alteration of the expression or function 
of enzymes of the miRNA processing, such as 
Drosha, Dicer or DGCR8, was reported in cancer
(22). 
In addition, many studies indicate that the 
microRNA expression may be also affected by 
different epigenetic mechanisms leading to the 
silencing of the tumor suppressor microRNA 
including abnormal methylation of the promoter 
regions (23) or histone modifications (24). 
Dysregulated miRNAs in breast cancer 
breast cancer is the most common cancer in women  
worldwide. Several methods such as Mammography 
and ultrasound imaging have been employed for 
diagnosis of breast cancer and prolonged patient 
survival, but they are known to have some 
limitations for early detection, sensitivity and 
specificity. Several studies have focused on 
dysregulated miRNAs as potential biomarkers for 
early diagnosis of breast cancer which could be used 
along with other methods of detection. ubnormal 
expression of miRNAs can be found in tissue or 
body fluids of patients. Here we want to review 
some studies which have been done in this area of 
research. MiR-21 is one of the most commonly 
studied oncomiRNAs which has been reported to be 
up-regulated in serum of BC patients compared with 
healthy controls (25-26). Li and collagues performed 
a meta-analysis of six studies in order to assesse 
diagnostic capacity of miR-21 in breast cancer 
patients and showed that miR-21 could be a specific 
and sensitive biomarker for early diagnosis of breast 
cancer (27).  
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Wu et al. (28) found the raised serum expression 
level of miR-21 and miR-29a in breast cancer 
patients using deep sequencing technique. 
According to a large cohort study which designed to 
identify expression level of serum miRNA, a total of 
1280 serum samples of breast cancer patients 
compared with healthy samples. As a result a 
combination of five miRNA (miR-1246, miR-1307-
3p, miR-4634, miR-6861-5p and miR-6875-5p) was 
found to be able to detect breast cancer at early stage 
(29).  
Moreover, Hagress et al quantified levels of 5 
miRNAs in sera of breast cancer patients and control 
samples. They found that expression of miR-10b, 
miR155, and miR195 in breast cancer patients was 
significantly up-regulated than control group and 
could be used as potential novel biomarkers for 
breast cancer (30). Also miR-195 was up-regulated 
in 148 patients in Heneghan et al. study (31). 
Another study which has been done by Iorio et al. 
identified 29 miRNAs that had significant 
differences in expression in breast cancer tissue 
compared to normal tissue. Among these miRNAs, 
miR-21 and miR-155 were up-regulated while miR 
10b, miR-125b and mR-145 were downregulated in 
the breast cancer tissue (32). Also Wang and 
collagues examined the expression level of some 
microRNAs in tissues and sera from breast cancer 
patients. The expression level of miR-21, miR-106a, 
and miR-155 was up-regulated and miR-126, miR-
199a, and miR-335 were down-regulated in tumor 
tissues in comparison with normal samples (33). 
A research that was done with Enders et al. reported 
the up-regulation of miR-16, miR-21 and miR-451 
in plasma of breast cancer patients. They also 
proposed that the signature of miR-451 and miR-145 
could be potential biomarkers for screening breast 
cancer (34).  
Aguilara and coworkers performed miRNA profiling 
on the serum of breast cancer patients and examined 
the sensitivity and specificity of miRNAs by 
construction of Receiver Operating Characteristic 
(ROC) curves. Seven miRNAs (miR-
10b/21/125b/145/155/191/382) had different 
expression levels in the serum of cancer patients 
compared to normal controls. With ROC curve 
analysis three serum miRNAs (miR-145, miR-155 
and miR-382) was suggested to be as novel 
noninvasive biomarkers for breast cancer detection
(35).  
References 
 
28. Wu Q, Lu Z Fau - Li H, Li H Fau - Lu J, Lu J Fau - Guo L, Guo L Fau - Ge Q and Ge Q: Next-generation 
sequencing of microRNAs for breast cancer detection. BioMed Research International 2011. 
29. Shimomura A, Shiino S, Kawauchi J, et al: Novel combination of serum microRNA for detecting breast cancer in 
the early stage. Cancer Sci 107: 326-334, 2016. 
30. Hagrass HA, Sharaf S, Pasha HF, Tantawy EA, Mohamed RH and Kassem R: Circulating microRNAs - a new 
horizon in molecular diagnosis of breast cancer. Genes Cancer 6: 281-287, 2015. 
31. Heneghan HM, Miller N Fau - Kelly R, Kelly R Fau - Newell J, Newell J Fau - Kerin MJ and Kerin MJ: Systemic 
miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive 
and early stage disease. Oncologist 15: 673-682, 2010. 
32. Iorio MV, Ferracin M Fau - Liu C-G, Liu Cg Fau - Veronese A, et al: MicroRNA gene expression deregulation in 
human breast cancer. Cancer Res 65: 7065-7070, 2005. 
33. Wang F, Zheng Z Fau - Guo J, Guo J Fau - Ding X and Ding X: Correlation and quantitation of microRNA 
aberrant expression in tissues and sera from patients with breast tumor. Gynecologic oncology 119: 586-593, 2010. 
34. Ng EK, Li R Fau - Shin VY, Shin Vy Fau - Jin HC, et al: Circulating microRNAs as specific biomarkers for breast 
cancer detection. PLoS One 8: e53141, 2013. 
35. Mar-Aguilar F, Mendoza-Ramirez Ja Fau - Malagon-Santiago I, Malagon-Santiago I Fau - Espino-Silva PK, et al: 
Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Disease markers 34: 163
-169, 2013. 
Vol. 3, No. 2, jun, 2017 
Adhami and  Sadeghi  2017. The Cancer Press, 3(2): 44-49                                                                                                                    48 
www.thecancerpress.com 
www.imaqpress.com  
Vol. 3, No. 2, jun, 2017 
Conclusion 
 Breast cancer is the most common cancer among females around the world that is the most prevalent cause of 
death among breast cancer patients. Thus detection of disease at early stages is very important and vital. A 
large body of studies have been done to investigate expression level of miRNAs which their results indicate 
prognostic and predictive values of cancer-related circulating miRNAs or tissue specific miRNAs in breast 
cancer patients. Various miRNAs have been recognized, in which their expression were deregulated in the 
blood or tissue of patients with breast cancer. Since miRNAs are detectable in body fluids such as blood at 
very early stages of cancer, they can be employed as non-invasive biomarkers. However, because many 
parameter such as small sample size, sample type, experimental methods of profiling, treatment/tumor 
heterogeneity, stage, ethnic differences affect the results, additional studies in larger homogeneous 
populations are required to investigate the value of these biomarkers. Moreover, new technologies, such as 
microRNA microarray and next-generation sequencing, could help identify new potential miRNA biomarkers.  
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